Half-Yearly Examination of Inventiva's Financial Strategy
Daix, France - Inventiva (Euronext Paris: IVA), a clinical-stage biopharmaceutical company specializing in oral small molecule therapies for metabolic dysfunction-associated steatohepatitis (MASH) and other conditions with substantial unmet medical needs, has unveiled its most recent half-year report concerning its liquidity agreement with Kepler Cheuvreux.
Liquidity Account Insights
As of December 31, 2024, the liquidity contract with Kepler Cheuvreux has yielded several important figures for Inventiva:
- Cash available: € 349,630.55
- Number of shares: 113,452
- Total buy-side executions in the semester: 1,281
- Total sell-side executions in the semester: 1,366
- Buy-side trade volume: 215,444 shares worth € 477,452.69
- Sell-side trade volume: 231,651 shares worth € 538,913.35
Comparatively, the previous half-year report as of June 30, 2024, disclosed:
- Cash available: € 285,764.46
- Number of shares: 129,659
- Total buy-side executions in the semester: 1,886
- Total sell-side executions in the semester: 1,610
- Buy-side trade volume: 322,578 shares worth € 1,074,534.26
- Sell-side trade volume: 276,147 shares worth € 938,985.90
Performance Reflection
Initially, at the contract's implementation, the liquidity account held resources including:
- Cash: € 163,510.42
- Number of shares: 34,063
Understanding Inventiva’s Market Position
Inventiva is dedicated to creating transformative therapies addressing pressing health needs. Its lead candidate, lanifibranor, is a pivotal focus within ongoing clinical trials, specifically regarding adult patients with MASH. This clinical advancement showcases the company's commitment to tackling chronic liver disease, an area of high medical necessity.
Inventiva’s pipeline also includes odiparcil, which aims to address treatment needs in adult MPS VI patients. Despite focusing primarily on lanifibranor, Inventiva is assessing future pathways for odiparcil's development, maintaining flexibility in its strategic approach.
With an adept team of approximately 90 professionals and extensive resources, including a proprietary library of pharmacologically relevant compounds, Inventiva is well-positioned to progress in its research and development efforts.
Future Development Goals
As Inventiva forges ahead, its focus remains on the clinical and regulatory progress of lanifibranor while exploring additional research avenues. The team continually seeks out promising candidates that align with its mission to transform healthcare.
Frequently Asked Questions
What is the main focus of Inventiva?
Inventiva focuses on developing oral small molecule therapies for MASH and other significant health conditions.
What financial performance was reported for December 2024?
As of December 31, 2024, Inventiva reported cash availability of € 349,630.55 and a total of 113,452 shares.
How is lanifibranor progressing in clinical trials?
Lanifibranor is currently involved in pivotal Phase III trials, specifically targeting adult patients with MASH.
What other products are in Inventiva's pipeline?
Inventiva's pipeline includes odiparcil, aimed at treating adult MPS VI patients, while the company reviews further development options.
What is the significance of the liquidity contract with Kepler Cheuvreux?
The liquidity contract with Kepler Cheuvreux facilitates market stability and enhances Inventiva's financial robustness during trading activities.
